Agoracom: Small Cap Investment - Zenith Epigenetics

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

AACR 2020 Poster

posted on Jun 29, 2020 07:21AM

Combination of ZEN-3694 with CDK4/6 inhibitors reverses resistance in ER-positive breast cancer

https://www.zenithepigenetics.com/upload/media_element/120/01/aacr-2020-1750-abstract-2346.pdf

https://www.abstractsonline.com/pp8/#!/9045/presentation/1852

7 Recommendations

Jun 29, 2020 08:28AM

Jun 29, 2020 01:08PM

Jun 29, 2020 03:40PM

Back To Forum List View

Please to post a reply